4-[(Piperidin-4-yl)methyl]morpholine → HCID 66715423, compound
Reaction equation
[Br:1][C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]=[CH:7][C:6]([C:12]([CH:14]1[CH2:16][CH2:15]1)=[O:13])=[C:5]2Cl.[NH:18]1[CH2:23][CH2:22][CH:21]([CH2:24][N:25]2[CH2:30][CH2:29][O:28][CH2:27][CH2:26]2)[CH2:20][CH2:19]1>>[Br:1][C:2]1[CH:3]=[C:4]2[C:9](=[CH:10][CH:11]=1)[N:8]=[CH:7][C:6]([C:12]([CH:14]1[CH2:16][CH2:15]1)=[O:13])=[C:5]2[N:18]1[CH2:23][CH2:22][CH:21]([CH2:24][N:25]2[CH2:30][CH2:29][O:28][CH2:27][CH2:26]2)[CH2:20][CH2:19]1Participants
3
Procedure
Following general procedure B, (6-bromo-4-chloroquinolin-3-yl)(cyclopropyl)methanone (144 mg, 0.460 mmol) was reacted with 4-(piperidin-4-ylmethyl)morpholine (102 mg, 0.552 mmol) to afford the desired product (177 mg, 84%) as a yellow solid: ESI MS m/z 458 [C23H28BrN3O2+H]+.
Sources & evidence
- ORD record
- ord-0bd46e9bfc104d9bbc3dc79b586ac1d9
- Source dataset
- uspto-grants-2015_09
- Patent number
- US09120749B2
Reaction notes
Loading…